| payload |
{"created_at":"2026-04-10T01:02:52.094 {"created_at":"2026-04-10T01:02:52.094973+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:169b3ce4cf7e3479","evidence_event_ids":["evt_4d6175bb4549"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/could-buying-dividend-pharma-stock-today-set-you-life","as_of":"2026-04-10T01:02:52.094973+00:00","canonical_url":"https://www.fool.com/investing/2026/04/09/could-buying-this-dividend-pharma-stock-today-set/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/could-buying-dividend-pharma-stock-today-set-you-life","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_d50be44e9bdca9bf","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/09/could-buying-this-dividend-pharma-stock-today-set/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T02:05:03.770010+00:00","extraction_method":"heuristic","fetched_description":"Key PointsJohnson & Johnson has an incredible dividend-increase streak spanning more than 60 years.","fetched_title":"Could Buying This Dividend Pharma Stock Today Set You Up for Life? | Nasdaq","final_url":"https://www.nasdaq.com/articles/could-buying-dividend-pharma-stock-today-set-you-life","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/could-buying-dividend-pharma-stock-today-set-you-life","source_event_id":"evt_4d6175bb4549","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"246d42465c28c1fd","kind":"unusual_volume","published_at":"2026-04-10T00:35:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 09, 2026","December 17, 2004","April 15, 2005"],"entities":[{"asset_class":"equity","name":"Johnson & Johnson","relevance":"high","symbol":"JNJ","type":"company"},{"asset_class":"equity","name":"Kenvue","relevance":"medium","symbol":"KVUE","type":"company"},{"asset_class":"equity","name":"Kimberly Clark","relevance":"low","symbol":"KMB","type":"company"},{"asset_class":"equity","name":"AbbVie","relevance":"low","symbol":"ABBV","type":"company"},{"asset_class":"equity","name":"Abbott Laboratories","relevance":"low","symbol":"ABT","type":"company"},{"asset_class":"index","name":"S&P 500","relevance":"low","symbol":"^GSPC","type":"index"}],"event_type":"other","information_gaps":["No ticker-specific unusual volume data is provided (no volume ratio vs average, no baseline volume, no direction).","No explicit catalyst for unusual volume is described; the article is a dividend-focused investment discussion rather than a market microstructure/volume event.","The signal type indicates unusual volume delta, but the provided text does not contain any confirmation or explanation tied to volume."],"key_facts":["The article states J&J is a \u201cDividend King\u201d with at least 50 consecutive annual dividend increases.","The article states J&J\u2019s dividend-increase streak is 63 years and is the longest among the healthcare Dividend Kings mentioned.","The article states J&J\u2019s consumer products group was spun off as Kenvue (KVUE).","The article states Kenvue has agreed to be acquired by Kimberly Clark (KMB).","The article states J&J is described as a pure-play healthcare business after the spin-off.","The article states J&J is diversified across drugs and medical devices.","The article states J&J plans to spin off its orthopedics business in 2027.","The article states J&J\u2019s drug business is nearly two-thirds of revenues.","The article states J&J\u2019s credit rating is AAA.","The article states J&J\u2019s dividend yield is roughly 2.2% and compares it to the S&P 500 yield of about 1.1%.","The article asks whether to buy J&J \u201cright now,\u201d but does not cite any trading-volume anomaly."],"numeric_claims":[{"label":"Dividend-increase streak (years)","value":"63"},{"label":"Other healthcare Dividend Kings streak (years)","value":"54"},{"label":"Dividend yield (percent)","value":"2.2"},{"label":"S&P 500 yield (percent)","value":"1.1"},{"label":"Target dividend yield (percent)","value":"4"},{"label":"Drug business share of revenues (percent, approx.)","value":"~66"},{"label":"Credit rating","value":"AAA"}],"primary_claim":"Johnson & Johnson has a 63-year streak of consecutive annual dividend increases (the longest among healthcare Dividend Kings).","relevance_score":0.15,"sentiment":"positive","source_quality":"high","summary":"The Motley Fool article discusses Johnson & Johnson (JNJ) as a long-term dividend stock, emphasizing its 63-year consecutive annual dividend increase streak and diversified healthcare business. It does not provide any unusual trading volume information or a volume ratio vs average.","topics":["dividend investing","Johnson & Johnson dividend streak","healthcare diversification","medical devices","spin-off plans","credit rating","yield"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsJohnson & Johnson has an incredible dividend-increase streak spanning more than 60 years.","tickers":[],"title":"Could Buying This Dividend Pharma Stock Today Set You Up for Life?","url":"https://www.fool.com/investing/2026/04/09/could-buying-this-dividend-pharma-stock-today-set/"}}... |